Immunotherapies for Life

Clinical Pipeline Highlights

Product Indication Development Phase

Pre-clin

Phase I

Phase I/II

Phase II

Phase III

131I-8H9 (B7-H3) Refractory Leptomeningeal Tumor Neuroblastoma
(ODD and RPDD)
75% Complete
131I-8H9 (B7-H3) Desmoplastic Small Round Cell Tumor
75% Complete
124I-8H9 (B7-H3) Diffuse Intrinsic Pontine Glioma
(RPDD)
75% Complete
131I-hu8H9 (B7-H3) B7-H3 positive LM tumors (Adult)
75% Complete
hu8H9 (B7-H3) Ovarian Cancer (Adult)
75% Complete
hu3F8 (GD2) Refractory/Relapsed Neuroblastoma
(ODD)
75% Complete
hu3F8 (GD2) Osteosarcoma (Pediatric)
(ODD)
75% Complete
hu3F8-BsAb (GD2xCD3) GD2 positive solid tumors (Adult)
75% Complete
hu3F8-BsAb (GD2xCD3) Refractory Neuroblastoma and Ewing's Sarcoma (Pediatric)
75% Complete

ODD represents Orphan Drug Designation in the US and RPDD is a Rare Pediatric Disease Designation

Overview

Y-mAbs Therapeutics, Inc (YmAbs) is a clinical-stage biopharmaceutical company developing novel antibody therapeutics for oncology targets based on a range of technologies licensed from Memorial Sloan Kettering Cancer Center (“MSK”) under an exclusive worldwide license and research collaboration agreement. YmAbs applies its world-class antibody capabilities to create life-changing immunotherapies for cancer patients of all ages. YmAbs’ innovative product candidates leverage its extensive drug development capabilities and its proprietary protein technology platform – MULTI TAG™.

Mission

YmAbs mission is to discover, develop and deliver novel antibody therapeutics for the treatment of both pediatric and adult cancer patients.

Company Highlights

  • YmAbs is a clinical stage biotechnology company specialized in developing novel antibody therapeutics to treat cancer
  • Memorial Sloan Kettering Cancer Center, the world’s largest and oldest private cancer institution, is YmAbs’ scientific collaboration partner and shareholder
  • From MSK, YmAbs has exclusive global rights to two clinical stage antibody programs with a strong validated clinical safety profile, treating more than 1,000 neuroblastoma patients. These programs are today used as “standard-of-care” treatment for patients at Memorial Sloan Kettering Cancer Center
  • Further, YmAbs has licensed a protein Multimerization Technology Platform – MULTI TAG™, incubated and developed at MSK to further enhance the therapeutic effect of antibodies
  • Several ongoing clinical trials significantly improve survival rates for critical unmet medical needs among cancer patients
  • YmAbs has a management team with proven track record and antibody drug development experience as well as expertise in running leading public biopharmaceutical companies